Only %1 left
Catalog #
102716
As low as $195 *
●
Purchase
●
Description
This anti-myostatin antibody is a purified, recombinant human monoclonal antibody that recognizes human myostatin, also known as growth differentiation factor 8 (GDF-8). This antibody has been tested in a binding assay. This antibody is similar to Apitegromab, also known as SRK-015.
●
Synonyms
Myostatin, Growth/differentiation factor 8, MSTN, GDF8, MSLHP, Apitegromab, SRK-015
●
Product Data Gallery
4-20% SDS-PAGE Coomassie Staining
Binding of Myostatin:Anti-Myostatin by ELISA.
GDF-8: Anti-Myostatin Binding Activity. Representative data only, data may vary by lot.
Product Info
Storage and Usage
Citations 0
Species
Human
Isotype
IgG4
Clonality
Monoclonal
Host Species/Expression System
HEK293
Purity
≥85%
Format
Aqueous buffer solution.
Formulation
8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol.
Target(s)
Myostatin
MW
Heavy chain: 50 kDa + glycans; Light chain: 23 kDa
Endotoxin Level
<1000 EU/mg
Glycosylation
This antibody runs at a higher MW by SDS-PAGE due to glycosylation.
UniProt #
O14793
Background
Myostatin, also known as Growth differentiation Factor 8 (GDF-8), is a secreted protein that is expressed specifically in developing and adult skeletal muscle. It controls myoblast proliferation and is a potent negative regulator of skeletal muscle mass. Myostatin belongs to the transforming growth factor β (TGF-β) superfamily. All TGF-β superfamily members are synthesized and secreted as a homodimeric pre-propeptide that is cleaved by proprotein convertases such as furin to generate the dimeric N- terminal propeptide and the dimeric C-terminal mature active protein. The C- terminal mature protein contains the characteristic conserved cysteine residues involved in the formation of the cysteine knot domain. Myostatin is highly conserved across species. Among TGF-β family members, Myostatin is most closely related to GDF-11/BMP-11. Myostatin-targeting drugs aim to increase muscle mass, including monoclonal antibodies such as apitegromab, domagrozumab, and landogrozumab, which are under investigation as therapeutics for diseases such as sarcophenia, muscular dystrophy, and spinal muscular atrophy (SMA). They may also be useful to avoid loss of muscle mass when taking weight loss drugs such as incretin analogs (GLP-1, GIPR, and glucagon analogs).
●
Datasheets/Protocols
Datasheets provide example lot-specific information. Contact us to request information on currently available lots.
●
Related Content
Service Inquiry